Oncology

Merck is set to complete the already planned purchase of the ArQule for USD 2.7 Billion. Under the terms of the agreement, Merck will pay USD 20 for each share in cash for a total amount of USD 2.7 Billion. ArQule is a biopharmaceutical, which is focused on kinase inhibitor discovery, finding cures for cancer patients. The takeover will help Merck to gain access to ArQule’s ARQ 531, an oral Bruton’s tyrosine kinase (BTK) inhibitor, which was the primary reason for the purchase. The drug, at present, is undergoing Phase II trials under evaluation for B-cell malignancies treatment. BTK inhibitors are promising agents that help to prevent the revelation to the...